Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 2
2007 2
2008 1
2010 1
2011 2
2012 3
2013 5
2014 4
2015 6
2016 9
2017 7
2018 9
2019 16
2020 12
2021 14
2022 10
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28217463

101 results

Results by year

Filters applied: . Clear all
Page 1
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P. Widmark A, et al. Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18. Lancet. 2019. PMID: 31227373 Clinical Trial.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A. Fransson P, et al. Lancet Oncol. 2021 Feb;22(2):235-245. doi: 10.1016/S1470-2045(20)30581-7. Epub 2021 Jan 11. Lancet Oncol. 2021. PMID: 33444529 Clinical Trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Aluwini S, et al. Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968359 Clinical Trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Aluwini S, et al. Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Lancet Oncol. 2015. PMID: 25656287 Clinical Trial.
Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL).
Murthy V, Mallick I, Gavarraju A, Sinha S, Krishnatry R, Telkhade T, Moses A, Kannan S, Prakash G, Pal M, Menon S, Popat P, Rangarajan V, Agarwal A, Kulkarni S, Bakshi G. Murthy V, et al. BMJ Open. 2020 Feb 28;10(2):e034623. doi: 10.1136/bmjopen-2019-034623. BMJ Open. 2020. PMID: 32114475 Free PMC article. Clinical Trial.
Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
Staal FHE, Janssen J, Brouwer CL, Langendijk JA, Ng Wei Siang K, Schuit E, de Jong IJ, Verzijlbergen JF, Smeenk RJ, Aluwini S. Staal FHE, et al. BMC Cancer. 2022 Apr 15;22(1):416. doi: 10.1186/s12885-022-09493-5. BMC Cancer. 2022. PMID: 35428210 Free PMC article.
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F. Incrocci L, et al. Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339116 Clinical Trial.
Hypofractionation for prostate cancer: an update.
Tiberi D, Vavassis P, Nguyen D, Yassa M. Tiberi D, et al. Expert Rev Endocrinol Metab. 2017 May;12(3):199-205. doi: 10.1080/17446651.2017.1324294. Expert Rev Endocrinol Metab. 2017. PMID: 30063454
101 results